As of November 10, 2026, Attovia Therapeutics, Inc. is a publicly traded company (Nasdaq: ATTO). The largest holder reporting an active stake on Schedule 13D is Frazier Life Sciences Public Fund, L.P., at 13.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Deep Track Capital (7.45%) (Schedule 13D, August 11, 2026).
Is this your company?
About to sign with, pay or invest in Attovia Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Attovia Therapeutics, Inc. a real, registered company?
- Attovia Therapeutics, Inc. files with the SEC under CIK 2058707 (its SEC filings).
- Its shares are listed under the ticker ATTO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Carlos, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Attovia Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Deep Track Capital (filed 2026-08-12).
Who are Attovia Therapeutics, Inc.'s owners and officers?
Attovia Therapeutics, Inc.: incorporated in Delaware; business address in San Carlos, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-08-12).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-12 | Deep Track Capital, LP | 7.45% |
| Schedule 13D, 2026-08-11 | Frazier Life Sciences Public Fund, L.P. | 13.5% |
Questions about who owns Attovia Therapeutics, Inc.
Who owns Attovia Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Attovia Therapeutics, Inc.: Frazier Life Sciences Public Fund, L.P. (13.5%, Schedule 13D, filed 2026-08-11) and Deep Track Capital, LP (7.45%, Schedule 13G, filed 2026-08-12).
Who are the largest shareholders of Attovia Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Attovia Therapeutics, Inc. on this page are Frazier Life Sciences Public Fund, L.P. (13.5%) and Deep Track Capital, LP (7.45%).
When did Frazier Life Sciences Public Fund, L.P. buy into Attovia Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Frazier Life Sciences Public Fund, L.P. on this page is the Schedule 13D, filed 2026-08-11, reporting 13.5%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Attovia Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Attovia Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Attovia Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Attovia Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , L.P., a 10% owner: 6,154,213 shares (13.5% of shares outstanding), on a joint filing (Form 4, 2026-08-06).
- , L.P., a 10% owner: 6,154,213 shares (13.5% of shares outstanding), on a joint filing (Form 4, 2026-08-06).
- , L.L.C., a 10% owner: 6,154,213 shares (13.5% of shares outstanding), on a joint filing (Form 4, 2026-08-06).
- venBio Global Strategic Fund IV, L.P., a 10% owner: 4,181,367 shares (9.1% of shares outstanding) (Form 4, 2026-08-10).
- Alamar HoldCo, LLC, a 10% owner: 3,229,278 shares (7.1% of shares outstanding) (Form 3, 2026-08-05).
Shares outstanding: 45,712,536 as of 2026-10-31, from the company's latest SEC cover page.
How much has Attovia Therapeutics, Inc. raised?
Latest IPO step: Attovia Therapeutics, Inc. filed its final IPO prospectus, ticker ATTO (424B4, 2026-08-05).
IPO filings: 424B4, 2026-08-05, S-1/A, 2026-08-04, S-1/A, 2026-07-29, S-1, 2026-07-14; ticker ATTO on Nasdaq Global Market.
Keep reading
More on Attovia Therapeutics, Inc. and the records around it.
Attovia Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Frazier Life Sciences Public Fund, L.P. also filed stake reports on 25 other companies: PHATHOM PHARMACEUTICALS, INC. (Nov 2026), Q32 Bio Inc. (Oct 2026), ACLARIS THERAPEUTICS, INC. (Sep 2026)
- Deep Track Capital, LP also filed stake reports on 59 other companies: Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/attovia-therapeutics